Drug discovery company, SCYNEXIS, Inc. today announced that multiple abstracts related to the Company's cyclophilin inhibitor, SCY-635, were accepted for presentation at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 14-18, 2010. SCY-635, a cyclophilin inhibitor, represents a new class of drugs for the treatment of hepatitis C virus (HCV) infection and is the first candidate from a broad platform of proprietary cyclophilin inhibitors developed by SCYNEXIS. Full abstracts can be viewed at the EASL website at www.easl.eu.
“In vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy”
SCY-635 Oral Presentation
"Resistance Selection Following 15 Days of Monotherapy with SCY-635 a Non-immunosuppressive Cyclophilin Inhibitor with Potent Anti-HCV Activity," Thursday, April 15, 2010, 17:45 to 18:00 CET.
SCY-635 Poster Presentations
"The Effects of SCY-635 a Non-immunosuppressive Cyclosporin Analog on Stellate Cell Proliferation, Collagen Synthesis, TIMP-1 and Collagenase Production," Friday, April 16, 2010
"In vitro Models for Assessing the Relative Risk of Hyperbilirubinemia Associated with Cyclophilin Inhibitor Therapy," Friday, April 16, 2010
Understanding metabolic alterations and immune dysfunction in acute-on-chronic liver failure